Kurome Therapeutics is developing therapies that inhibit IRAK1 and IRAK4 to target cancer cells that exploit immune signaling pathways to evade destruction by conventional treatments. This dual inhibition approach aims to enhance therapeutic efficacy in hematological malignancies by preventing adaptive resistance mechanisms.
Funding
$79M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AAFounders
Product
Problem
Many cancer cells exploit immune signaling pathways to evade destruction by conventional treatments, leading to adaptive resistance and reduced therapeutic efficacy, particularly in hematological malignancies. Single-target kinase inhibitors may be insufficient due to compensatory mechanisms within these signaling pathways.
Solution
Kurome Therapeutics is developing therapies that employ dual inhibition of IRAK1 and IRAK4 to target cancer cells that have co-opted immune signaling pathways. By simultaneously inhibiting both kinases, the approach aims to prevent adaptive resistance mechanisms and enhance therapeutic efficacy in hematological malignancies. Pre-clinical studies have demonstrated that inhibiting both IRAK1 and IRAK4 is required to drive maximal efficacy, as IRAK1 can be activated in response to IRAK4 inhibition. Complete inhibition of NF-kB-derived signaling through multiple receptors necessitates the inhibition of both IRAK1 and IRAK4.
Target Audience
The primary target audience includes patients with hematological malignancies, as well as oncologists and researchers focused on developing more effective cancer therapies.
Features
- Dual inhibition of IRAK1 and IRAK4 kinases.
- Designed to prevent adaptive resistance mechanisms in cancer cells.
- Aims to enhance therapeutic efficacy in hematological malignancies.
- Addresses the compensatory activation of IRAK1 following IRAK4 inhibition.
- Targets NF-kB-derived signaling through multiple receptors.